Phase II trial of irinotecan plus s-1 (IRIS) with cetuximab (IRIS/Cet) as second-line treatment in patients with KRAS wild-type metastatic colorectal cancer (mCRC): HGCSG0902-Comparison of administration interval in cetuximab treatment.

被引：0
|
作者：
Komatsu, Yoshito
Yuki, Satoshi
Nakatsumi, Hiroshi
Hosokawa, Ayumu
Nakamura, Michio
Muto, Osamu
Meguro, Takashi
Iwanaga, Ichiro
Hatanaka, Kazuteru
Tsuji, Yasushi
Sato, Atsushi
Eto, Kazunori
Furukawa, Kouichi
Onodera, Manabu
Tateyama, Miki
Takahashi, Yasuo
Dazai, Masayoshi
Yokoyama, Sachio
Honda, Takuya
Sakata, Yuh
机构：
[1] Hokkaido Univ Hosp, Ctr Canc, Dept Canc Chemotherapy, Sapporo, Hokkaido 060, Japan
[2] Hokkaido Univ Hosp, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido 060, Japan
[3] Toyama Univ, Fac Med, Dept Gastroenterol & Hematol, Toyama 930, Japan
[4] Sapporo City Gen Hosp, Dept Gastroenterol, Sapporo, Hokkaido, Japan
[5] Japanese Red Cross Akita Hosp, Dept Med Oncol, Akita, Japan
[6] Hokkaido Gastroenterol Hosp, Sapporo, Hokkaido, Japan
[7] Japanese Red Cross Kitami Hosp, Dept Gastroenterol, Kitami, Hokkaido, Japan
[8] Hakodate Municipal Hosp, Dept Gastroenterol, Hakodate, Hokkaido, Japan
[9] Tonan Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan
[10] Hirosaki Univ, Grad Sch Med, Dept Med Oncol, Hirosaki, Aomori, Japan
[11] Tomakomai City Hosp, Dept Gastroenterol, Tomakomai, Japan
[12] Niigata City Gen Hosp, Niigata, Japan
[13] Abashiri Kosei Gen Hosp, Dept Gastroenterol, Abashiri, Japan
[14] Tomakomai Nisshou Hosp, Dept Internal Med, Tomakomai, Japan
[15] Hokkaido Canc Ctr, Dept Gastroenterol, Sapporo, Hokkaido, Japan
[16] Kushiro Rosai Hosp, Dept Internal Med, Kushiro, Hokkaido, Japan
[17] Kumamoto City Hosp, Dept Surg, Kumamoto, Japan
[18] Nagasaki Univ, Dept Gastroenterol & Hepatol, Grad Sch Biomed Sci, Nagasaki 852, Japan
[19] Misawa City Hosp, Misawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
10.1200/jco.2015.33.3_suppl.746
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
746
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Updated analysis of phase II trial of irinotecan/s-1/cetuximab (IRIS/Cet) as second-line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer (mCRC): HGCSG0902-Comparison of administration interval in cetuximab treatment.
    Kondo, Tomohiro
    Yuki, Satoshi
    Kawamoto, Yasuyuki
    Tsuji, Yasushi
    Hosokawa, Ayumu
    Nakamura, Michio
    Muto, Osamu
    Kato, Takashi
    Iwanaga, Ichiro
    Sato, Atsushi
    Eto, Kazunori
    Furukawa, Kouichi
    Hayashi, Hideyuki
    Tateyama, Miki
    Takahashi, Yasuo
    Sogabe, Susumu
    Honda, Takuya
    Sakata, Yuh
    Komatsu, Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [2] Final analysis: phase II trial of Irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC: HGCSG0902. -comparison of administration interval in cetuximab treatment
    Yuki, S.
    Komatsu, Y.
    Nakatsumi, H.
    Kawamoto, Y.
    Muranaka, T.
    Sawada, K.
    Tsuji, Y.
    Hosokawa, A.
    Nakamura, M.
    Muto, O.
    Sasaki, T.
    Iwanaga, I.
    Hatanaka, K.
    Sato, A.
    Eto, K.
    Furukawa, K.
    Tateyama, M.
    Takahashi, Y.
    Sogabe, S.
    Honda, T.
    Sakamoto, N.
    Sakata, Y.
    ANNALS OF ONCOLOGY, 2016, 27 : 43 - 43
  • [3] Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment
    Ando, T.
    Yuki, S.
    Nakatsumi, H.
    Muranaka, T.
    Hosokawa, A.
    Tsuji, Y.
    Nakamura, M.
    Muto, O.
    Sasaki, T.
    Iwanaga, I.
    Hatanaka, K.
    Sato, A.
    Eto, K.
    Furukawa, K.
    Tateyama, M.
    Takahashi, Y.
    Sogabe, S.
    Honda, T.
    Sakata, Y.
    Komatsu, Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Updated analysis: Phase II trial of irinotecan plus S-1 (IRIS) with cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type metastatic colorectal cancer (mCRC): HGCSG0902
    Hosokawa, A.
    Yuki, S.
    Kawamoto, Y.
    Ando, T.
    Muto, O.
    Nakamura, M.
    Kato, T.
    Iwanaga, I.
    Hatanaka, K.
    Tsuji, Y.
    Sato, A.
    Eto, K.
    Furukawa, K.
    Okuda, H.
    Hayashi, H.
    Fujikawa, K.
    Kudo, M.
    Honda, T.
    Sakata, Y.
    Komatsu, Y.
    ANNALS OF ONCOLOGY, 2015, 26 : 49 - 50
  • [5] Phase II trial of Irinotecan plus S-1 (IRIS) with Cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type of metastatic colorectal cancer (mCRC): HGCSG0902 updated analysis
    Nakamura, M.
    Yuki, S.
    Nakatsumi, H.
    Muto, O.
    Hosokawa, A.
    Kato, T.
    Iwanaga, I.
    Hatanaka, K.
    Tsuji, Y.
    Sato, A.
    Eto, K.
    Furukawa, K.
    Okuda, H.
    Onodera, M.
    Fujikawa, K.
    Kudo, M.
    Yokoyama, S.
    Honda, T.
    Sakata, Y.
    Komatsu, Y.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S360 - S360
  • [6] Safety report of a phase II trial of irinotecan plus S-1 (IRIS) with cetuximab in patients with KRAS wild type of metastatic colorectal cancer: HGCSG0902.
    Komatsu, Yoshito
    Yuki, Satoshi
    Kato, Takashi
    Hosokawa, Ayumu
    Iwanaga, Ichiro
    Muto, Osamu
    Hatanaka, Kazuteru
    Nakamura, Michio
    Tsuji, Yasushi
    Sakata, Yuh
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] SAFETY REPORT OF A PHASE II TRIAL OF IRINOTECAN PLUS S-1 (IRIS) WITH CETUXIMAB IN PRE-TREATED PATIENTS WITH KRAS WILD TYPE OF METASTATIC COLORECTAL CANCER: HGCSG0902
    Komatsu, Y.
    Yuki, S.
    Kawamoto, Y.
    Hayashi, H.
    Kato, T.
    Hosokawa, A.
    Iwanaga, I.
    Muto, O.
    Hatanaka, K.
    Nakamura, M.
    Tsuji, Y.
    Tateyama, M.
    Fukushima, H.
    Kudo, M.
    Sakata, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 87 - 87
  • [8] A phase II trial of panitumumab with irinotecan and S-1 (IRIS) as second-line treatment in patients with wild-type KRAS metastatic colorectal cancer.
    Shimoyama, Rai
    Kimura, Tetsuo
    Takaoka, Toshi
    Sakamoto, Kazuki
    Kawamoto, Shunji
    Yoshizaki, Koji
    Negoro, Yuji
    Goda, Fuminori
    Tsuji, Akihito
    Nakayama, Tsuyoshi
    Miyamoto, Hiroshi
    Takayama, Tetsuji
    Niitsu, Yoshiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [9] A PHASE II STUDY OF CETUXIMAB PLUS IRINOTECAN/S-1 AS FIRST-LINE TREATMENT IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER
    Masuishi, T.
    Sakai, Y.
    Matsui, T.
    Nakamura, R.
    Anzai, S.
    Suzuki, Y.
    Kobori, I.
    Fukami, Y.
    Suzuki, K.
    Tazawa, J.
    ANNALS OF ONCOLOGY, 2013, 24
  • [10] A phase II study of cetuximab in combination with irinotecan plus S-1 as first-line treatment in patients with KRAS wild-type metastatic colorectal cancer: CIRIS study
    Masuishi, T.
    Sakai, Y.
    Matsui, T.
    Nakamura, R.
    Anzai, S.
    Suzuki, Y.
    Kobori, I.
    Fukami, Y.
    Suzuki, K.
    Tazawa, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S557 - S557
12345